ImmunityBio (IBRX) just received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cancer immunotherapy, ANKTIVA, which targets bladder cancer. This designation is a strong signal that the treatment has significant potential and allows for an expedited regulatory pathway, potentially leading to faster approval and commercialization.
If ANKTIVA continues to show strong results in trials, it could lead to sustained growth, a higher valuation, and possibly even partnerships or acquisition interest from larger pharmaceutical companies.
With an accelerated regulatory pathway now in place, the next few weeks could be interesting for IRBX.
Positions:
10,000 share at a $3.50 average
50 $4c 3/21
